Understanding saRNA capping for vaccine development - TriLink BioTechnologies

Self-amplifying RNA, or saRNA, is a promising approach to vaccine development. Using the alphavirus backbone, saRNA replicates inside cells, providing its potential effectiveness even at low doses. But accurately replicating the natural starting sequence of saRNA is crucial. Here's where capping comes in.
First, enzymatic capping offers flexibility, but it’s often multi-step and expensive for large-scale production. Plus, saRNA's size makes it prone to degradation during purification,
And secondary structures may make it difficult for enzymes to access the 5′ end.
Second, ARCA capping can be faster than enzymatic, but it creates a non-optimal structure and uses a different starting sequence, potentially affecting function and causing unwanted immune reactions. It also competes with GTP, reducing capping efficiency.
Finally, capping with TriLink’s CleanCap AU analog streamlines the process, circumventing these issues. It produces an optimal cap structure with the desired 5′ AU sequence at high yield and efficiency, translating to a faster, cheaper, and more reliable way to manufacture saRNA vaccines and therapeutics.
Learn more at trilinkbiotech...

[@austintao8763]

very interesting!